Daraxonrasib combined with standard chemotherapy achieved a median progression-free survival exceeding one year in patients with metastatic pancreatic ductal adenocarcinoma, according to updated phase 1/2 clinical trial data.
The findings, presented at the 2026 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, show that the combination of daraxonrasib (Rasonque) with gemcitabine and nab-paclitaxel (GnP) resulted in a 60.7% confirmed objective response rate. Among the 61 patients enrolled in the first-line cohort of the RMC-GI-102 study, 8.2% achieved complete responses, meaning no cancer was detectable on scans. Patients were followed for a median of 18.3 months.
Trial Shows Durable Disease Control with 12-Month Survival Rate
Patients in the trial experienced durable disease control, with the median duration of response lasting 11.1 months. Researchers reported a 12-month overall survival rate of 76.6%, while median progression-free survival reached 12.8 months as of the September 28, 2026, data cutoff.
I've lost multiple dear friends to pancreatic cancer – the therapeutic progress in the past 24 months brings me joy and relief. We live in an age of miracles.https://t.co/tYkLeRuwI9
“With longer follow-up and a larger patient population, we are seeing a notable combination of high response rates, including deep complete responses, and durable disease control, with median [PFS] exceeding [1] year,” said Wungki Park, a medical oncologist at Memorial Sloan Kettering Cancer Center, in a press statement. Park presented the results as a late-breaking oral abstract (8LBA) in Barcelona, Spain.
“We are beginning to see not only a higher percentage of tumour response rates, but also deeper responses and a near doubling in the duration of disease control, which may eventually translate into longer survival,” said Wungki Park, a medical oncologist at Memorial Sloan Kettering Cancer Center.

Ongoing Phase 3 Investigations
The current results support the design of the ongoing RASolute 303 trial, which is evaluating daraxonrasib both as a monotherapy and in combination with chemotherapy against chemotherapy alone in treatment-naïve patients. Revolution Medicines, the manufacturer of the drug, expects this larger study to provide further clarity on the treatment’s long-term utility across different RAS genotypes.
While the drug was approved by the FDA in August 2026 for patients who have already undergone at least one prior treatment, its use as a first-line therapy remains under investigation. Analysts at Truist Securities have suggested that potential approval for this first-line indication could occur by 2028.
From @CNN to @BBC ! 🌍💜💜 As a pancreatic cancer specialist, I rarely see results like these in metastatic #PDAC. 8% CONFIRMED CR 12.8-month median PFS, which exceeds medial OS of standard chemotherapy (11.1 months) in this setting. 3 out of 4 (~76%) were alive at 12 months!…
Perspectives on Treatment Progress
The medical community has described the results as an important step forward for a disease historically characterized by low survival rates. Dr. Sam Godfrey of Cancer Research UK said that the findings represent "the biggest leap forward in decades" for patients, noting that the drug effectively targets mutations previously considered difficult to treat.
“What this new drug has done is it's found a way of drugging the undruggable.” Dr Sam Godfrey of Cancer Research UK told BBC News.
During #PancreaticCancerAwareness month learn more about how the new FDA-approved metastatic pancreatic cancer treatment daraxonrasib works. @DanaFarber's Andrew Aguirre, MD, PhD explains in this video with @TargetedOnc CC: @DanaFarber_Hale https://t.co/F3ySTdYwuG
“I would hope that the early success that we are beginning to see in pancreatic cancer can also be rolled out to other cancers,” Dr Godfrey said. He said longer trials and results were vital. “Cancer can come back and even if scans show there is no sign of it, you don’t necessarily know you are cancer-free until more time has passed.”
However, clinical experts emphasize that these outcomes do not constitute a cure. Because pancreatic cancer is prone to recurrence, researchers note that longer follow-up is necessary to determine the duration of remission.

Drug Availability Limited to US Patients After Prior Treatment
Is daraxonrasib currently available for all pancreatic cancer patients?
No. The drug is currently licensed in the US for patients whose cancer has progressed after at least one previous treatment or who cannot tolerate combination chemotherapy. It is not yet available on the NHS in the UK, where it remains restricted to clinical trials.
What is the mechanism of action for this treatment?
Daraxonrasib is a KRAS inhibitor designed to lock onto and deactivate specific mutations known as RAS, which drive tumor growth in the majority of pancreatic cancers.
Memorial Sloan Kettering Cancer Center was formed in 1980 by merging Memorial Hospital for the Treatment of Cancer and Allied Diseases, founded in 1884, with the adjacent Sloan-Kettering Institute for Cancer Research, founded in 1945; the two entities had formally coordinated operations since 1960.
How can patients access these trials?
Patients are encouraged to consult their oncology teams regarding the availability of the RASolute trials and to discuss whether genomic testing of their tumors for KRAS mutations is appropriate.